Amylin-Induced Migraine Attacks Without Aura

ConditionsHeadache Disorders, Primary Headache Disorders Brain Diseases Nervous System Diseases Central Nervous System Diseases Neurologic Manifestations Signs and Symptoms Pathological Conditions, Signs and Symptoms Migraine Disorders Headache Pain Peptide Hormones Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Peptides Amino Acids, Peptides, and Proteins Amylin Pramlintide

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-65

SponsorDanish Headache Center

About this trial

Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.

Eligibility criteria

Qualifiers

Age 18 to 65 years of age upon entry into screening

A body weight of 50 to 100 kg

History of migraine without aura for ≥12 months and in accordance with ICHD-3

Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening

Disqualifiers

Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache

Any history of moderate to severe traumatic brain injury

Any history of cardiovascular disease, including cerebrovascular diseases

Any history of pulmonary disease

Trial design

Treatments tested in this trial

Amylin
Placebo

Treatment groups

21 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Danish Headache Center

Lead sponsor

Source ClinicalTrials.gov